Etiqueta: heart failure

From the medical journal PloS ONE, scientists from the University of California Los Angeles reported that human blood cells derived from adult stem cells can be engineered into cells that can target and kill HIV-infected cells.

Doctors at the University of Texas Medical School at Houston have announced initiation of an efficacy-finding study in the area of heart failure using a "universal donor" stem cell product called "Prochymal".

The study demonstrated efficacy in the treated patients based on increase cardiac muscle contraction ability as compared to patients that had bypass surgery but did not receive stem cells.

In a recent paper the use of mesenchymal stem cells was evaluated after the cells have been stored frozen.

A paper published today from the Mary Laughlin’s group describes the use of cord blood cells in creation of new blood vessels.

Today NOXXON announced that is has successfully administered its NOX-A12 aptamer-based mobilizer to healthy volunteers as part of a Phase I clinical trial.

The adult stem cell company Aldagen Inc, from Durham North Carolina announced today that it has filed a registration with the Securities Exchange Commission for an initial public offering with a potential value of $80.5 million.

In yet another heart disease study, adult stem cells derived from adipose tissue are chosen as the most promising therapy.

The adult stem cell company Cardio3 BioSciences presents an update on its heart failure therapy at the annual conference of the European Society of Cardiology.